Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBD-rich cannabis oil is an extract from the Cannabis sativa plant that contains high concentrations of cannabidiol (CBD) and low levels of tetrahydrocannabinol (THC). Unlike THC, CBD is not psychoactive and does not produce a "high." The primary mechanism of action involves modulation of the endocannabinoid system by interacting with cannabinoid receptors in the body, which are involved in regulating pain sensation, inflammation, mood, and other physiological processes. CBD-rich oils are used for a variety of potential therapeutic purposes including seizure disorders (notably Dravet syndrome and Lennox-Gastaut syndrome), chronic pain management, anxiety reduction, anti-inflammatory effects, sleep disorders such as insomnia, and as adjunctive therapy for certain neurological conditions. The only FDA-approved prescription form of pure CBD is Epidiolex for specific types of epilepsy; however, over-the-counter CBD oils are widely available but lack regulatory approval for medical indications[1][2][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cbd-rich cannabis oil.